Stocks · News reference
Truist Securities Downgrades Lantheus Holdings to Hold, Lowers Price Target to $102.5
Truist Securities analyst Richard Newitter downgrades Lantheus Holdings (NASDAQ:LNTH) from Buy to Hold and lowers the price target from $125 to $102.5.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — Lantheus Holdings, Inc. (LNTH)
Filed: 2026-09-21 AccNo: 0001193125-26-396654 Size: 159 KB Item 8.01: Other Events
Curium™ announces FDA approval of BEXLUTRY lutetium Lu 177 dotatate injection for adults with SSTR-positive GEP-NETs
Curium announced FDA approval of BEXLUTRY, a radioligand therapy for treating somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adults. The approval marks Curium's first radioligand therapy and represents expansion into oncology therapeutics. The company also announced acquisitions of Abscint SA and a definitive merger agreement with Lantheus to create a global radiopharmaceutical leader.
FDA Approves Lantheus Imaging Drug for Alzheimer's Diagnostics
Lantheus receives FDA approval for PET imaging agent used to evaluate adults for Alzheimer's disease by identifying tau pathology.